• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company

    9/10/25 4:37:30 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care
    Get the next $SHC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Sotera Health Co

    (Name of Issuer)


    Common Stock, par value $0.01 per share

    (Title of Class of Securities)


    83601L102

    (CUSIP Number)


    09/05/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WP XI Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the U.S. Securities and Exchange Commission ("Commission") September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS PRIVATE EQUITY XI, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS XI PARTNERS, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission on September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS PRIVATE EQUITY XI-B, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS PRIVATE EQUITY XI-C, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    BULL CO-INVEST L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS XI, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WP GLOBAL LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS PARTNERS II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    103,038,253.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    61,822,952.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS PARTNERS GP LLC.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS & CO.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS (CAYMAN) XI, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS XI-C, LLC.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS PARTNERS II (CAYMAN), L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS (BERMUDA) PRIVATE EQUITY GP LTD.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,038,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    61,822,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,038,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    36.3 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), of which 41,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities' Form 4, filed with the Commission September 9, 2025. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below. (2) Calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Sotera Health Co
    (b)Address of issuer's principal executive offices:

    9100 South Hills Blvd, Suite 300 Broadview Heights, OH 44147
    Item 2. 
    (a)Name of person filing:

    This Amendment No. 2 to Schedule 13G is being filed jointly by Warburg Pincus XI, L.P., a Delaware limited partnership ("WP XI GP"), is the general partner of each of (i) Warburg Pincus Private Equity XI, L.P. ("WP XI"), (ii) Warburg Pincus Private Equity XI-B, L.P. ("WP XI-B"), (iii) WP XI Partners, L.P. ("WP XI Partners") and (iv) Warburg Pincus XI Partners, L.P. ("Warburg Pincus XI Partners"). WP Global LLC ("WP Global"), is the general partner of WP XI GP. Warburg Pincus Partners II, L.P. ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners GP LLC ("WPP GP LLC"), is the general partner of WPP II. Warburg Pincus & Co. ("WP"), is the managing member of WPP GP LLC. Warburg Pincus (Cayman) XI, L.P. ("WP XI Cayman GP"), is the general partner of Warburg Pincus Private Equity XI-C, L.P. ("WP XI-C" and, together with WP XI, WP XI-B, WP XI Partners and Warburg Pincus XI Partners, the "WP XI Funds"). The WP XI Funds, Bull Co-Invest, Bull Holdco, WP Global, WPP II, WPP GP LLC, WP XI Cayman GP, WP XI-C LLC, WPP II Cayman, WP Bermuda GP, WP Bull Manager, WP LLC and WP are collectively referred to herein as the "Warburg Pincus Entities." Warburg Pincus XI-C, LLC ("WP XI-C LLC"), is the general partner of WP XI Cayman GP. Warburg Pincus Partners II (Cayman), L.P. ("WPP II Cayman"), is the managing member of WP XI-C LLC. Warburg Pincus (Bermuda) Private Equity GP Ltd. ("WP Bermuda GP"), is the general partner of WPP II Cayman. WP Bull Manager LLC ("WP Bull Manager"), is the general partner of Bull Co-Invest. WP is managing member of WP Bull Manager. Warburg Pincus LLC, a New York limited liability company ("WP LLC"), is the manager of the WP XI Funds. The WP XI Funds share limited partnership ownership in Bull Holdco on a pro rata basis in accordance with their respective numbers of Contributed Shares. The WP XI Funds, Bull Co-Invest, WP XI-C, WP XI LP, WP Global, WPP II, WPP GP LLC, WP Cayman, Warburg Pincus XI-C, WPP II Cayman, Warburg Pincus (Bermuda), WP Bull Manager, WP LLC and WP are collectively referred to herein as the "Warburg Pincus Reporting Persons or WP Investors."
    (b)Address or principal business office or, if none, residence:

    Warburg Pincus Reporting Persons is 450 Lexington Avenue, New York, New York 10017
    (c)Citizenship:

    See Item 2(a).
    (d)Title of class of securities:

    Common Stock, par value $0.01 per share
    (e)CUSIP No.:

    83601L102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page hereto for each Warburg Pincus Reporting Person and is incorporated herein by reference for each such Warburg Pincus Reporting Person. On November 19, 2020, (i) the Issuer, (ii) Warburg Pincus Private Equity XI, L.P., Warburg Pincus Private Equity XI_B, L.P., Warburg Pincus Private Equity XI-C, L.P., WP XI Partners, L.P. and Bull Co-Invest (collectively, the "Warburg Pincus Sponsors"), (iii) GTCR Fund XI/A LP, GTCR Fund XI/C LP, and GTCR Co-Invest XI LP. (collectively, the "GTCR Funds") and (iv) certain other holders of Common Stock of the issuer ( the "Other Investors"), entered into a Stockholders Agreement (the "Stockholders Agreement"). The Stockholders Agreement sets forth certain governance arrangements with respect to the Issuer, transfer restrictions on Other Investors and indemnification matters. Pursuant to the Stockholders Agreement, each of the Warburg Pincus Sponsors and the GTCR Funds has agreed to vote the shares of Common Stock of the Issuer that each holds of record in a certain manner on matters related to the election of certain directors appointed by the Warburg Pincus Sponsors and the GTCR Sponsors. The Warburg Pincus Sponsors and the GTCR Sponsors hold an aggregate total of 103,038,253 shares of Common Stock of the Issuer (approximately 36.3% of the outstanding shares of Common Stock of the Issuer), including 41,215,301 shares of Common Stock of the Issuer that are publicly reported as being owned by the GTCR Sponsors and 61,822,952 shares of Common Stock of the Issuer that are publicly reported as being owned by the Warburg Pincus Reporting Persons. The Warburg Pincus Reporting Persons are not entitled to any rights as a shareholder of the Issuer with respect to the shares of Common Stock of the Issuer beneficially owned by the Other Investors or the GTCR Sponsors except as expressly set forth in the Stockholders Agreement and the Warburg Pincus Reporting Persons do not have dispositive power over the Common Stock owned by the GTCR Sponsors. Each Warburg Pincus Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock of the Issuer other than the shares of Common Stock of the Issuer owned of record by such Warburg Pincus Reporting Person. The number of shares of Common Stock of the Issuer owned by each Warburg Pincus Reporting Person as set forth in Rows 5 - 11 of their respective cover pages to this Schedule 13G does not reflect the aggregate shares of Common Stock of the Issuer owned by the Other Investors. The aggregate total of 41,215,301 shares of Common Stock of the Issuer indicated in this Amendment No. 2 to Schedule 13G as being beneficially owned by the GTCR Sponsors is derived from the GTCR Sponsors' Form 4, filed with the Commission on September 9, 2025, and is not purported to be an accurate representation of the GTCR Sponsors' beneficial ownership as of the date of this Amendment No. 2 to Schedule 13G. The GTCR Sponsors are responsible for reporting their beneficial ownership of shares of Common Stock of the Issuer on their own behalf, and the Warburg Pincus Reporting Persons disclaim responsibility for reporting the shares of Common Stock of the Issuer beneficially owned by the GTCR Sponsors.
    (b)Percent of class:

    The percentages used herein are calculated based on 284,046,606 shares of Common Stock outstanding as of July 29, 2025 as reported on the Issuer's final prospectus reported on Form 424B7, filed on September 3, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0.00

     (ii) Shared power to vote or to direct the vote:

    103,038,253

     (iii) Sole power to dispose or to direct the disposition of:

    0.00

     (iv) Shared power to dispose or to direct the disposition of:

    61,822,952

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Other than as set forth herein, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, in excess of 5% of the total outstanding Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    (1) The Warburg Pincus Reporting Persons are making this single, joint filing because they may be deemed to constitute a "group" within the meaning of the Exchange Act. The joint filing agreement among the Warburg Pincus Reporting Persons to file this Amendment No. 2 to Schedule 13G jointly in accordance with Rule 13d-1(k) of the Exchange Act is incorporated by reference as Exhibit 99.1. (2) Each Warburg Pincus Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock of the Issuer other than the shares of Common Stock of the issuer owned of record by such Warburg Pincus Reporting Person.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    WP XI Partners, L.P.
     
    Signature:/s/ Warburg Pincus XI, L.P.
    Name/Title:Warburg Pincus XI, L.P / General Partner
    Date:09/09/2025
     
    Signature:/s/ WP Global LLC
    Name/Title:WP Global LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners II, L.P.
    Name/Title:Warburg Pincus Partners II, L.P. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:09/09/2025
     
    WARBURG PINCUS PRIVATE EQUITY XI, L.P.
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti, Partner
    Date:09/09/2025
     
    Signature:/s/ WP Global LLC
    Name/Title:WP Global LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners II, L.P.
    Name/Title:Warburg Pincus Partners II, L.P. / Managing Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Partner
    Date:09/09/2025
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:09/09/2025
     
    WARBURG PINCUS XI PARTNERS, L.P.
     
    Signature:/s/ Warburg Pincus XI, L.P.
    Name/Title:Warburg Pincus XI, L.P. / General Partner
    Date:09/09/2025
     
    Signature:/s/ WP Global LLC
    Name/Title:WP Global LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners II, L.P.
    Name/Title:Warburg Pincus Partners II, L.P. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:09/09/2025
     
    WARBURG PINCUS PRIVATE EQUITY XI-B, L.P.
     
    Signature:/s/ Warburg Pincus XI, L.P.
    Name/Title:Warburg Pincus XI, L.P. / General Partner
    Date:09/09/2025
     
    Signature:/s/ WP Global LLC
    Name/Title:WP Global LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners II, L.P.
    Name/Title:Warburg Pincus Partners II, L.P. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:09/09/2025
     
    WARBURG PINCUS PRIVATE EQUITY XI-C, L.P.
     
    Signature:/s/ Warburg Pincus (Cayman) XI, L.P.
    Name/Title:Warburg Pincus (Cayman) XI, L.P. / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus XI-C, LLC
    Name/Title:Warburg Pincus XI-C, LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners II (Cayman), L.P.
    Name/Title:Warburg Pincus Partners II (Cayman), L.P. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus (Bermuda) Private Equity GP Ltd.
    Name/Title:Warburg Pincus (Bermuda) Private Equity GP Ltd. / General Partner
    Date:09/09/2025
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Authorised Signatory
    Date:09/09/2025
     
    BULL CO-INVEST L.P.
     
    Signature:/s/ WP Bull Manager LLC
    Name/Title:WP Bull Manager LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Memeber
    Date:09/09/2025
     
    WARBURG PINCUS XI, L.P.
     
    Signature:/s/ WP Global LLC
    Name/Title:WP Global LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners II, L.P.
    Name/Title:Warburg Pincus Partners II, L.P. / Manging Member
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners GP LLC.
    Name/Title:Warburg Pincus Partners GP LLC. / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Manging Member
    Date:09/09/2025
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:09/09/2025
     
    WP GLOBAL LLC
     
    Signature:/s/ Warburg Pincus Partners II, L.P.
    Name/Title:Warburg Pincus Partners II, L.P. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partners
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:09/09/2025
     
    WARBURG PINCUS PARTNERS II, L.P.
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:09/09/2025
     
    WARBURG PINCUS PARTNERS GP LLC.
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti
    Date:09/09/2025
     
    WARBURG PINCUS & CO.
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:09/09/2025
     
    WARBURG PINCUS (CAYMAN) XI, L.P.
     
    Signature:/s/ Warburg Pincus XI-C, LLC
    Name/Title:Warburg Pincus XI-C, LLC / General Partner
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus Partners II (Cayman), L.P.
    Name/Title:Warburg Pincus Partners II (Cayman), L.P. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus (Bermuda) Private Equity GP Ltd.
    Name/Title:Warburg Pincus (Bermuda) Private Equity GP Ltd. / General Partner
    Date:09/09/2025
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Authorised Signatory
    Date:09/09/2025
     
    WARBURG PINCUS XI-C, LLC.
     
    Signature:/s/ Warburg Pincus Partners II (Cayman), L.P.
    Name/Title:Warburg Pincus Partners II (Cayman), L.P. / Managing Member
    Date:09/09/2025
     
    Signature:/s/ Warburg Pincus (Bermuda) Private Equity GP Ltd.
    Name/Title:Warburg Pincus (Bermuda) Private Equity GP Ltd. / General Partner
    Date:09/09/2025
     
    Signature:/s/ / Harsha Marti
    Name/Title:Harsha Marti / Authorised Signatory
    Date:09/09/2025
     
    WARBURG PINCUS PARTNERS II (CAYMAN), L.P.
     
    Signature:/s/ Warburg Pincus (Bermuda) Private Equity GP Ltd.
    Name/Title:Warburg Pincus (Bermuda) Private Equity GP Ltd. / General Partner
    Date:09/09/2025
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Authorised Signatory
    Date:09/09/2025
     
    WARBURG PINCUS (BERMUDA) PRIVATE EQUITY GP LTD.
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Authorised Signatory
    Date:09/09/2025
     
    WARBURG PINCUS LLC
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Managing Director
    Date:09/09/2025
    Exhibit Information

    Exhibit 99.1 Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.* * Incorporated herein by reference to the Agreement of Joint Filing by Warburg Pincus Private Equity XI, L.P., Warburg Pincus XI Partners, L.P., Warburg Pincus Private Equity XI-B, L.P., WP XI Partners, L.P., Warburg Pincus Private Equity XI-C, L.P., Bull Co-Invest L.P., Warburg Pincus XI, L.P., WP Global LLC, Warburg Pincus Partners II, L.P., Warburg Pincus Partners GP LLC, Warburg Pincus & Co., Warburg Pincus (Cayman) XI, L.P., Warburg Pincus XI-C, LLC, Warburg Pincus Partners II (Cayman), L.P., Warburg Pincus (Bermuda) Private Equity GP LTD., and Warburg Pincus LLC ("Warburg Pincus Funds") dated as of February 14, 2022, which was previously filed with the Commission as Exhibit 99.1 to Amendment No. 1 to Schedule 13G filed by the Warburg Pincus Funds on February 14, 2022 with respect to the shares of common stock of Sotera Health Co.

    Get the next $SHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SHC

    DatePrice TargetRatingAnalyst
    5/5/2025$17.00Neutral → Buy
    Goldman
    12/6/2024$14.00Neutral
    Goldman
    5/21/2024$13.00Neutral
    Piper Sandler
    4/3/2024$18.00 → $16.00Neutral → Buy
    Citigroup
    3/25/2024$15.00 → $15.50Hold → Buy
    Jefferies
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    6/26/2023$24.00Sector Weight → Overweight
    KeyBanc Capital Markets
    1/23/2023$6.00 → $18.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sotera Health Announces Secondary Offering of Common Stock

    CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC) (the "Company") today announced the launch of a secondary offering (the "Offering") of 20,000,000 shares of its common stock, par value $0.01 per share. All 20,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC ("Warburg Pincus") and GTCR LLC ("GTCR") as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Regist

    9/3/25 4:57:13 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results

    Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues outlook to 4.5% - 6.0% and Adjusted EBITDA outlook to 6.0% - 7.5%, on a constant currency basis CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera He

    8/8/25 7:30:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Second-Quarter 2025 Earnings Release Date

    CLEVELAND, July 28, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the second-quarter ended June 30, 2025 before the market opens on Friday, August 8, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations. A live

    7/28/25 7:38:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sotera Health upgraded by Goldman with a new price target

    Goldman upgraded Sotera Health from Neutral to Buy and set a new price target of $17.00

    5/5/25 8:27:32 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Goldman initiated coverage on Sotera Health with a new price target

    Goldman initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $14.00

    12/6/24 8:14:45 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Piper Sandler initiated coverage on Sotera Health with a new price target

    Piper Sandler initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $13.00

    5/21/24 7:45:20 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company

    SCHEDULE 13G/A - Sotera Health Co (0001822479) (Subject)

    9/10/25 4:37:30 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 8-K filed by Sotera Health Company

    8-K - Sotera Health Co (0001822479) (Filer)

    9/5/25 4:16:04 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 424B7 filed by Sotera Health Company

    424B7 - Sotera Health Co (0001822479) (Filer)

    9/4/25 4:16:06 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Warburg Pincus & Co. sold $181,332,000 worth of shares (12,000,000 units at $15.11) (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    9/9/25 9:41:32 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Director Warburg Pincus & Co. sold $181,332,000 worth of shares (12,000,000 units at $15.11) (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    9/9/25 9:37:53 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Director Gtcr Investment Xi Llc sold $120,888,000 worth of shares (8,000,000 units at $15.11) (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    9/9/25 8:41:57 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Financials

    Live finance-specific insights

    View All

    Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results

    Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues outlook to 4.5% - 6.0% and Adjusted EBITDA outlook to 6.0% - 7.5%, on a constant currency basis CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera He

    8/8/25 7:30:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Second-Quarter 2025 Earnings Release Date

    CLEVELAND, July 28, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the second-quarter ended June 30, 2025 before the market opens on Friday, August 8, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations. A live

    7/28/25 7:38:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Reports First-Quarter 2025 Results

    Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

    5/1/25 7:38:53 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/12/24 5:53:58 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Leadership Updates

    Live Leadership Updates

    View All

    Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

    CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

    1/6/25 4:30:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services

    Sotera Health Appoints Karen Flynn to Board of Directors

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials